Risk factors

Kairos Pharma (KAPA) risk factors

Item 1A of every Kairos Pharma, Ltd. 10-K on file, and what changed from one year to the next.

Open KAPA in Gloomberb →
  • FY2025 10-K risk factors

    93 risks, 2 new, 1 dropped, 2 reworded since the prior year. New risks focus on rapid U.S. policy changes, including taxation and healthcare, and reduced access to debt and equity capital.

    Filed Mar 31, 2026
  • FY2024 10-K risk factors

    92 risks. Kairos Pharma faces extensive risks typical of early-stage biotechnology firms, dominated by severe funding needs, single-source manufacturing dependencies, and heavy reliance on key management.

    Filed Apr 15, 2025